BnR Summit 2025

Belt and Road Summit 2025- Deal-making

10 – 16 Sept 2025 | China (Hong Kong)

ProjectUpdated on 4 September 2025

Novel Platinum-Based Drug (HJ-550 )

Haiyang Wang

CEO at Shanghai Haiju Biotechnology Co., Ltd.

Shanghai, China

About

A first-in-class targeted bivalent platinum drug exhibits overall superior efficacy over first-line standard-of-care treatments as monotherapy and in combination, holding potential to transform first-line tumor therapeutic strategies.

Project Location

  • China

Project Format

  • Private Project

ESG (Environmental, Social, and Governance)

  • Yes

Project Stage

  • Feasibility Study Completed

Main Project Sector

  • Technology

Technology

  • Bio-Tech

Interested Format of Cooperation

  • Joint Venture
  • Minority Shareholdings
  • Open for Negotiation
  • R&D Cooperation

Preferred Financing Model

  • Equity

Previous Funding Stage

  • Seed & Pre-Series

Main Service(s) Required

  • Financial Services
  • Professional Services

Financial Services

  • Investment Banking
  • Private Equity & Venture Capital

Professional Services

  • Business Valuation
  • Corporate Services
  • Legal Advisory

Attached files

Organisation

Similar opportunities